3 news items
Why Intellia Therapeutics Shares Are Trading Higher Monday
NTLA
3 Jun 24
in vivo CRISPR-based therapy, patients experienced durable elimination of their attacks. We are thrilled to see that the majority
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
NTLA
2 Jun 24
in vivo CRISPR-based therapy, patients experienced durable elimination of their attacks. We are thrilled to see that the majority of patients have
Cathie Wood's Ark Innovation ETF Sees Sharp Decline Among Top Holdings — Here Are 10-Largest Losers Within ARKF
DNA
NTLA
PACB
28 May 24
(NYSE:ARKK) has been navigating through significant losses, showcasing the challenges faced by some of its major holdings
- Prev
- 1
- Next